Der Dämpfer vom vergangenen Donnerstag hat Spuren hinterlassen. Die Markteilnehmer erholen sich nur sehr zaghaft. Hinzu kam, dass heute keine nennenswerten Wirtschaftsdaten veröffentlicht wurden,
News
Dow Jones – Aufwärtstrend intakt
Der Dow Jones Industrial Average® Index Future deutet auf einen stabilen Auftakt in den Handelstag hin. Nach dem Kursprung in der vergangenen Woche haben die Investoren einen Gang zurückgeschalten
Top-ESG-Ratings für Temenos: Dow Jones Sustainability Index, S&P Yearbook, Sustainalytics und EcoVadis
Temenos ist führend beim Übergang zu einem nachhaltigeren Bankwesen mit Software-as-a-Service
GENF, Schweiz, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN) wurde bei den renommiertesten
Dow Jones deutet Pause nach dem steilen Anstieg an
Der Dow Jones Industrial Average® Index hangelte sich in der abgelaufenen Woche von Rekord zu Rekord. Zugpferde des Anstiegs in der vergangenen Woche waren unter anderem die Aktien von Amgen
Jim Cramer Sees “Uniform Negativity” on Wall Street: Is a Bounce Coming?
For better or for worse, Mad Money host Jim Cramer is the face of the financial markets for many retail traders and investors. With his penchant for bright lights and shouting, Cramer's doesn't
September Speculations in Railroads, Real Estate and Russian Rubles
For weekend reading, Gary Alexander, senior writer at Navellier & Associates, offers the following commentary:
In the last 25 years, three events have haunted us, and they all share an
REE bestätigt FMVSS-Zertifizierungsfähigkeit seiner X-by-Wire-Systeme im Vorfeld der Fahrzeugzertifizierung im 4. Quartal 2023
– Gemeinsame Tests mit HORIBA-MIRA bestätigen die Machbarkeit des X-by-Wire-Fahrzeugsteuerungssystems von REE zur Erfüllung der FMVSS-Zertifizierungsanforderungen– REE beabsichtigt die vollständige
A Tale Of Two Debt Downgrades – A Bang (2011) And A Whimper (2023)
For weekend reading, Gary Alexander, senior writer at Navellier & Associates, offers the following commentary:
What is it about the first week of August in the third year of a Biden/Obama first
The Bountiful Science – Economics
For weekend reading, Gary Alexander, senior writer at Navellier & Associates, offers the following commentary:
In 1849, the Scotsman Thomas Carlyle dubbed a new field of study called Economics,
Can the Dow's 2023 Runaway Winners Keep Running?
April showers really do bring May flowers.
Following a rather cloudy April, U.S. stock indices have blossomed to fresh 2023 highs in May. With the technology sector the standout performer, the
Nearly 4 In 5 Advisors Say The U.S. Economy Is In A Recession – Or Will Be Within The Year – 2023 Survey
According to the official definition of a recession, Americans haven’t entered one1. But despite what many economists are saying, advisors in the trenches see it differently.
In a survey of
Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
Cortexyme, Inc. (Nasdaq: CRTX) announced that Casey Lynch, chief executive officer, co-founder, and chair, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference
Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
Cortexyme, Inc. (Nasdaq: CRTX) will present additional data from its Phase 2/3 GAIN Trial at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting’s
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
Cortexyme, Inc. (Nasdaq: CRTX) announced that it will participate at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting’s Late-Breaking Readout
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
Cortexyme, Inc. (Nasdaq: CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an
Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal Phase 2/3 trial in Alzheimer’s disease and a growing pipeline of therapeutics for degenerative diseases, today announced that it will
Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative
Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative
Cortexyme Provides Business Update and Reports Second Quarter 2021 Results
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative
Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for
Cortexyme to Present New Data at AAIC 2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for